title: Adverse effects of dopamine potentiation by long-term treatment with selegiline.
abstract: A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase-B platelet activity was low in this patient.
authors.affiliation: Department of Cell Biology, National Blood Transfusion Service, Budapest, Hungary. hollan@ella.hu
authors.forename: Susan
authors.initials: S
authors.lastname: Hollán
authors.forename: László
authors.initials: L
authors.lastname: Vécsei
authors.forename: Kálmán
authors.initials: K
authors.lastname: Magyar
mesh_terms: D000293:Adolescent; D000328:Adult; D000745:Anemia, Hemolytic, Congenital / Q000201:enzymology / Q000235:genetics*; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001418:Baclofen / Q000009:adverse effects / Q000627:therapeutic use; D001479:Basal Ganglia / Q000187:drug effects; D001480:Basal Ganglia Diseases / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D001792:Blood Platelets / Q000201:enzymology; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000209:etiology*; D004422:Dystonia Musculorum Deformans / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics*; D005260:Female; D006580:Genetic Carrier Screening; D005838:Genotype; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000172:deficiency* / Q000235:genetics; D006801:Humans; D000071058:Huntingtin Protein; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood / Q000235:genetics; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D009419:Nerve Tissue Proteins / Q000235:genetics; D009460:Neurologic Examination / Q000187:drug effects; D018696:Neuroprotective Agents / Q000009:adverse effects* / Q000627:therapeutic use; D009687:Nuclear Proteins / Q000235:genetics; D016133:Polymerase Chain Reaction; D011506:Proteins / Q000235:genetics; D011605:Psychoses, Substance-Induced / Q000175:diagnosis / Q000209:etiology*; D012016:Reference Values; D012642:Selegiline / Q000009:adverse effects* / Q000627:therapeutic use; D018911:Trinucleotide Repeats
chemical_list: D000978:Antiparkinson Agents; C086055:HTT protein, human; D000071058:Huntingtin Protein; D008996:Monoamine Oxidase Inhibitors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D009687:Nuclear Proteins; D011506:Proteins; D012642:Selegiline; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases; D008995:Monoamine Oxidase; D001418:Baclofen